Oculis Holding AG (NASDAQ:OCS) Given Average Recommendation of “Moderate Buy” by Brokerages

by · The Cerbat Gem

Shares of Oculis Holding AG (NASDAQ:OCS – Get Free Report) have been given an average recommendation of “Moderate Buy” by the ten research firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and nine have given a buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $38.3333.

A number of analysts have issued reports on OCS shares. HC Wainwright reiterated a “buy” rating on shares of Oculis in a research note on Thursday, June 11th. Guggenheim dropped their price objective on shares of Oculis from $75.00 to $45.00 and set a “buy” rating for the company in a report on Monday, June 1st. Needham & Company LLC cut their target price on shares of Oculis from $46.00 to $38.00 and set a “buy” rating on the stock in a research note on Monday, June 1st. Wall Street Zen lowered shares of Oculis from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Oculis in a research report on Tuesday, April 21st.

Check Out Our Latest Stock Report on OCS

Oculis Stock Performance

Shares of NASDAQ OCS opened at $14.12 on Friday. The company has a current ratio of 5.18, a quick ratio of 5.18 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $818.68 million, a PE ratio of -6.63 and a beta of 0.44. Oculis has a twelve month low of $10.52 and a twelve month high of $34.47. The stock has a fifty day simple moving average of $20.49 and a 200-day simple moving average of $23.86.

Oculis (NASDAQ:OCS – Get Free Report) last posted its earnings results on Friday, May 8th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.14). Oculis had a negative return on equity of 56.78% and a negative net margin of 8,460.67%.The firm had revenue of $0.26 million for the quarter, compared to analyst estimates of $0.25 million. On average, equities analysts forecast that Oculis will post -2.27 earnings per share for the current year.

Institutional Trading of Oculis

Several hedge funds have recently modified their holdings of OCS. Gildi lifeyrissjodur purchased a new position in Oculis in the fourth quarter valued at $50,250,000. Aberdeen Group plc increased its holdings in Oculis by 39.4% during the 4th quarter. Aberdeen Group plc now owns 1,746,946 shares of the company’s stock worth $34,887,000 after purchasing an additional 493,827 shares during the period. SR One Capital Management LP increased its holdings in Oculis by 98.8% during the 4th quarter. SR One Capital Management LP now owns 641,022 shares of the company’s stock worth $12,801,000 after purchasing an additional 318,522 shares during the period. Perceptive Advisors LLC acquired a new stake in Oculis in the 4th quarter valued at about $9,862,000. Finally, Alyeska Investment Group L.P. raised its position in Oculis by 152.3% in the 4th quarter. Alyeska Investment Group L.P. now owns 331,332 shares of the company’s stock valued at $6,617,000 after purchasing an additional 200,000 shares in the last quarter. 22.30% of the stock is currently owned by institutional investors and hedge funds.

Oculis Company Profile

(Get Free Report)

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.

Further Reading